NeuroPace, Inc. (NASDAQ:NPCE) to Post FY2023 Earnings of ($1.34) Per Share, Leerink Partnrs Forecasts

NeuroPace, Inc. (NASDAQ:NPCEFree Report) – Equities research analysts at Leerink Partnrs issued their FY2023 earnings per share estimates for NeuroPace in a report issued on Tuesday, January 30th. Leerink Partnrs analyst M. Kratky expects that the company will post earnings per share of ($1.34) for the year. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($1.36) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q4 2023 earnings at ($0.30) EPS, Q3 2024 earnings at ($0.31) EPS, FY2024 earnings at ($1.27) EPS and FY2025 earnings at ($1.15) EPS.

NPCE has been the subject of several other reports. JPMorgan Chase & Co. lifted their price objective on NeuroPace from $6.00 to $9.00 and gave the company an “overweight” rating in a report on Tuesday, November 7th. Cantor Fitzgerald assumed coverage on NeuroPace in a report on Friday, November 10th. They issued an “overweight” rating and a $11.00 price objective for the company. Lake Street Capital restated a “buy” rating and issued a $12.00 price objective on shares of NeuroPace in a report on Wednesday, December 27th. Morgan Stanley lifted their price objective on NeuroPace from $8.00 to $9.00 and gave the company an “equal weight” rating in a report on Monday, December 4th. Finally, SVB Leerink assumed coverage on NeuroPace in a report on Tuesday. They issued an “outperform” rating and a $22.00 price objective for the company. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $12.00.

Check Out Our Latest Report on NeuroPace

NeuroPace Stock Performance

NPCE stock opened at $14.99 on Thursday. The company has a debt-to-equity ratio of 3.42, a current ratio of 6.55 and a quick ratio of 5.79. The business has a 50-day moving average price of $10.84 and a 200 day moving average price of $8.12. The company has a market capitalization of $393.94 million, a P/E ratio of -9.99 and a beta of 2.14. NeuroPace has a 1-year low of $3.01 and a 1-year high of $15.56.

NeuroPace (NASDAQ:NPCEGet Free Report) last released its earnings results on Monday, November 6th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.11. NeuroPace had a negative return on equity of 151.83% and a negative net margin of 62.96%. The business had revenue of $16.43 million during the quarter, compared to the consensus estimate of $14.23 million.

Institutional Investors Weigh In On NeuroPace

Large investors have recently modified their holdings of the business. Kent Lake Capital LLC grew its stake in shares of NeuroPace by 16.9% during the second quarter. Kent Lake Capital LLC now owns 149,205 shares of the company’s stock worth $670,000 after acquiring an additional 21,529 shares during the last quarter. State Street Corp lifted its holdings in shares of NeuroPace by 2.1% during the first quarter. State Street Corp now owns 98,717 shares of the company’s stock worth $810,000 after purchasing an additional 2,042 shares during the period. BlackRock Inc. lifted its holdings in shares of NeuroPace by 11.2% during the second quarter. BlackRock Inc. now owns 36,117 shares of the company’s stock worth $162,000 after purchasing an additional 3,646 shares during the period. Citadel Advisors LLC acquired a new stake in shares of NeuroPace during the second quarter worth about $108,000. Finally, Geode Capital Management LLC lifted its holdings in shares of NeuroPace by 9.1% during the fourth quarter. Geode Capital Management LLC now owns 71,515 shares of the company’s stock worth $106,000 after purchasing an additional 5,945 shares during the period. Hedge funds and other institutional investors own 67.69% of the company’s stock.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, insider Martha Morrell sold 1,923 shares of NeuroPace stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $15.08, for a total value of $28,998.84. Following the transaction, the insider now owns 96,014 shares in the company, valued at $1,447,891.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Martha Morrell sold 1,923 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $15.08, for a total transaction of $28,998.84. Following the sale, the insider now owns 96,014 shares in the company, valued at $1,447,891.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ltd. Kck sold 6,490 shares of the business’s stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $8.96, for a total value of $58,150.40. Following the sale, the insider now owns 5,614,621 shares in the company, valued at approximately $50,307,004.16. The disclosure for this sale can be found here. Insiders have sold 30,359 shares of company stock worth $282,455 over the last quarter. Insiders own 27.50% of the company’s stock.

NeuroPace Company Profile

(Get Free Report)

NeuroPace, Inc operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

Featured Stories

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.